source
- Undecimal Bio raises $18 million to expand siRNA platform beyond liver diseasesUndecimal Bio, founded by Yaniv Erlich and Shaul Ilan, announced a new financing round that brings in $18 million. The capital will support the company’s effort to develop siRNA therapeutics for ta…
- Merck’s deeper dive into efficacy, safety of $1.3B eye disease drug raises fears of ‘limited’ potentialMerck & Co. has poured out its Brunello data, revealing a mix of undifferentiated efficacy and concerning safety that led analysts to predict “limited competitive potential” in diabetic macular ede…